Posted on June 20, 2021 by Sitemaster
Back in 1989, the SWOG 8494 trial first showed that adding an antiandrogen (flutamide) to bilateral medical orchiectomy with an LHRH agonist (leuprolide acetate) extended median overall survival (OS) by 7 months in newly diagnosed men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone-sensitive, metastatic, mHSPC, overall, survival, SWOG 1216 | 1 Comment »
Posted on February 4, 2021 by Sitemaster
Early in 2020, in the initial stages of the COVID-19 pandemic, there was a suggestion (based on data from a small Italian study) that men who were using androgen deprivation therapy (ADT) to manage their prostate cancer might be at lower than average risk for becoming infected with this virus. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, COVID-19, risk | 3 Comments »
Posted on September 11, 2017 by Sitemaster
A presentation at the ongoing annual meeting of the European Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen deprivation, docetaxel, hormone-sensitive, metastatic, mHSPC | 4 Comments »
Posted on October 21, 2015 by Sitemaster
Some recent randomized clinical trials have shown that adding androgen deprivation therapy (ADT) to radiation therapy can improve outcomes in some circumstances. However, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cardiovascular, radiation, risk, side effect | 2 Comments »
Posted on May 16, 2015 by Sitemaster
It’s now a relatively rare occurrence (about 12 percent of new patients) to be newly diagnosed with pelvic lymph node positive (N1) prostate cancer. Traditionally, this had been treated with ADT only because radiation therapy (RT) was thought to be of no benefit in extending survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, N+, N1, node-positive, radiation | 8 Comments »
Posted on February 17, 2015 by Sitemaster
So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, dutasteride, IADT, IADT3, intermittent | 34 Comments »
Posted on October 23, 2014 by Sitemaster
In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, CHAARTED, docetaxel, metastatic, treatment-naive | 1 Comment »
Posted on October 22, 2014 by Sitemaster
A newly published study has added to the mounting evidence that resistance training and related exercises are a valuable complement to medical care for men on androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ADT, androgen deprivation, esistance, exercise, quality of life, training | 3 Comments »
Posted on September 11, 2014 by Sitemaster
Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: androgen deprivation, brachytherapy, outcome, survival | 4 Comments »
Posted on June 1, 2014 by Sitemaster
So the data from the CHAARTED trial will be presented this afternoon at the ASCO meeting. This is the one really major and positive study result related to prostate cancer that we knew was coming at this meeting. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, chemohormonal, docetaxel, metastatic | 16 Comments »
Posted on December 27, 2013 by Sitemaster
According to a review article recently published in the Journal of Clinical Oncology, “Among patients … treated with androgen-deprivation therapy, appropriately prescribed exercise is safe and may ameliorate a range of treatment-induced adverse effects.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, exercise | 7 Comments »
Posted on December 6, 2013 by Sitemaster
According to a media release issued yesterday by the National Institutes of Health, the CHAARTED clinical trial has shown that men with hormone-sensitive, metastatic prostate cancer who received docetaxel chemotherapy at the start of standard androgen deprivation therapy (ADT) lived longer than patients who received ADT alone. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, chemotherapy, docetaxel, metastaic | 17 Comments »
Posted on October 10, 2013 by Sitemaster
According to a report on Practice Update last Monday, some interesting data were presented at a plenary session at the annual meeting of the American Society for Radiation Oncology (ASTRO) based on 10-year follow-up of men in the RTOG 9910 trial. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, intermediate, neoadjuvant, radiation, risk | 7 Comments »
Posted on May 2, 2013 by Sitemaster
It has been brought to our attention that the Southwest Oncology Group (SWOG) has initiated a new, randomized, double-blind, multi-center, Phase III trial designed to compare androgen deprivation therapy (ADT) + bicalutamide (Casodex) to ADT + the investigational drug TAK-700 in men newly diagnosed with metastatic, hormone-sensitive prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone-sensitive, metastatic, orteronel, TAK-700 | 9 Comments »
Posted on April 9, 2013 by Sitemaster
It has long been understood that treatment of prostate cancer with androgen deprivation therapy (ADT) can both increase the risk for diabetes among non-diabetic patients and can decrease sensitivity to insulin among men with diabetes. What has been missing, however, are good data about how ADT affects diabetes control among men with diabetes. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, diabetes, HbA1c | 1 Comment »
